FIELD: neurology.
SUBSTANCE: invention proposes: use of xenon being N-methyl-D-aspartic acid antagonist in function of neuroprotector and/or synaptic activity inhibitor, a method ensuring neuroprotection and/or synaptic activity inhibition, a method of preparing pharmaceutical composition and a pharmaceutical composition with indicated destination, and use of xenon to prepare pharmaceutical agent for neuroprotection and/or synaptic activity inhibition. Invention is distinguished by revealed possibility for known N-methyl-D-aspartic acid antagonist to decrease, by more than 30%, glutamate-caused damage of neurons and glia cells. In case of prolonged action of xenon, indicated damage can be additionally decreased by more than 55%.
EFFECT: expanded possibilities in neuroprotection field.
14 cl, 15 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANESTHETIC COMPOSITION COMPRISING NMDA-ANTAGONIST AND ALPHA-2-ADRENERGIC AGONIST | 2000 |
|
RU2244558C2 |
| COMPOUNDS BEING ACTIVE AT A NEW SITE UPON RECEPTOR-OPERATED CALCIUM CANALS APPLIED FOR TREATING NEUROLOGICAL DISORDERS | 1996 |
|
RU2246300C2 |
| COMBINED DRUG FOR PRIMARY NEUROPROTECTION | 2017 |
|
RU2636616C1 |
| MODULATOR OF NMDA-RECEPTOR WITH STABILISED SECONDARY STRUCTURE AND ITS USAGE | 2011 |
|
RU2566821C2 |
| DERIVATIVES OF 5B-SAPOGENIN AND PSEUDO SAPOGENIN AND APPLICATION FOR DEMENTIA MEDICAL TREATMENT | 2000 |
|
RU2325396C2 |
| COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR | 2015 |
|
RU2721948C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE | 2012 |
|
RU2618412C2 |
| THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR POTENTIAL DIABETES | 2008 |
|
RU2467743C2 |
| CYCLOPROPYLPIPERIDINE GLYCINE TRANSPORTER INHIBITORS | 2005 |
|
RU2387644C2 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
